Details

Autor(en) / Beteiligte

• Moffa, Adriano H.
• Martin, Donel
• Alonzo, Angelo
• Bennabi, Djamila
• Blumberger, Daniel M.
• Benseñor, Isabela M.
• Daskalakis, Zafiris
• Fregni, Felipe
• Haffen, Emmanuel
• Lisanby, Sarah H.
• Padberg, Frank
• Palm, Ulrich
• Razza, Lais B.
• Sampaio-Jr, Bernardo
• Loo, Colleen
• Brunoni, Andre R.

Titel

Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis

Ist Teil von

• Progress in neuro-psychopharmacology & biological psychiatry, 2020-04, Vol.99, p.109836-109836, Article 109836

Ort / Verlag

England: Elsevier Inc

Erscheinungsjahr

2020

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• We evaluated the efficacy and acceptability of transcranial direct current stimulation (tDCS) for treating acute depressive episodes using individual patient data that provide more precise estimates than aggregate data meta-analysis. A systematic review of placebo-controlled trials on tDCS as only intervention was conducted until December-2018. Data from each study was collated to estimate odds ratio (OR) and number needed to treat (NNT) of response and remission, and depression improvement. Endpoints were pre-determined. Nine eligible studies (572 participants), presenting moderate/high certainty of evidence, were included. Active tDCS was significantly superior to sham for response (30.9% vs. 18.9% respectively; OR = 1.96, 95%CI [1.30–2.95], NNT = 9), remission (19.9% vs. 11.7%, OR = 1.94 [1.19–3.16], NNT = 13) and depression improvement (effect size of β = 0.31, [0.15–0.47]). Moreover, continuous clinical improvement was observed even after the end of acute tDCS treatment. There were no differences in all-cause discontinuation rates and no predictors of response were identified. To conclude, active tDCS was statistically superior to sham in all outcomes, although its clinical effects were moderate. •Active tDCS was significantly superior to sham in all outcomes.•tDCS clinical effects were moderate.•There were no differences in all-cause discontinuation rates between tDCS and sham.•No predictors of response were identified.•Continuous clinical improvement was observed even after the end of acute treatment.